CORCEPT THERAPEUTICS INC Cash and Restricted Cash
CORCEPT THERAPEUTICS INC (CORT) had Cash and Restricted Cash of $112.29 million as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-07-29
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $112.29M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $109.99M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $121.75M; Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed $120.50M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $125.14M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $112.29M 10-Q · filed 2026-07-29 | |
| 2026-03-31 | $109.99M 10-Q · filed 2026-04-30 | |
| 2025-12-31 | $121.75M 10-Q · filed 2026-07-29 | $120.50M 10-K · filed 2026-02-24 |
| 2025-09-30 | $125.14M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $103.75M 10-Q · filed 2026-07-29 | $102.75M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $90.82M 10-Q · filed 2026-04-30 | $89.82M 10-Q · filed 2025-05-05 |
| 2024-12-31 | $128.66M 10-Q · filed 2026-07-29 | $127.67M 10-K · filed 2025-02-26 |
| 2024-09-30 | $137.29M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $128.59M 10-Q · filed 2025-07-31 | |
| 2024-03-31 | $149.75M 10-Q · filed 2025-05-05 | |
| 2023-12-31 | $135.55M 10-K · filed 2026-02-24 | |
| 2023-09-30 | $111.80M 10-Q · filed 2024-10-30 | |
| 2023-06-30 | $172.38M 10-Q · filed 2024-07-29 | |
| 2023-03-31 | $299.94M 10-Q · filed 2024-05-01 | |
| 2022-12-31 | $66.33M 10-K · filed 2026-02-24 | |
| 2022-09-30 | $50.24M 10-Q · filed 2023-11-01 | |
| 2022-06-30 | $35.35M 10-Q · filed 2023-08-02 | |
| 2022-03-31 | $61.86M 10-Q · filed 2023-05-03 | |
| 2021-12-31 | $77.62M 10-K · filed 2025-02-26 | |
| 2021-09-30 | $94.69M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $95.43M 10-Q · filed 2022-08-04 | |
| 2021-03-31 | $52.38M 10-Q · filed 2022-05-05 | |
| 2020-12-31 | $76.19M 10-K · filed 2024-02-15 | |
| 2020-09-30 | $30.56M 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $58.52M 10-Q · filed 2021-07-29 | |
| 2020-03-31 | $84.48M 10-Q · filed 2021-05-06 | |
| 2019-12-31 | $31.27M 10-K · filed 2023-02-28 | |
| 2019-09-30 | $44.95M 10-Q · filed 2020-11-03 | |
| 2019-06-30 | $58.14M 10-Q · filed 2020-08-04 | |
| 2019-03-31 | $49.65M 10-Q · filed 2020-05-04 | |
| 2018-12-31 | $41.63M 10-K · filed 2022-02-15 | |
| 2018-09-30 | $33.89M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $31.16M 10-Q · filed 2019-08-01 | |
| 2018-03-31 | $33.12M 10-Q · filed 2019-05-09 | |
| 2017-12-31 | $31.06M 10-K · filed 2021-02-23 | |
| 2017-09-30 | $31.06M 10-Q · filed 2018-11-02 | |
| 2017-06-30 | $33.62M 10-Q · filed 2018-08-09 | |
| 2016-12-31 | $51.54M 10-Q · filed 2018-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |